| Literature DB >> 35685508 |
Amir Motamedi1, Mohammadreza Askari2, Hadis Mozaffari3, Reza Homayounfrar4,5, Ali Nikparast5, Maryam Lafzi Ghazi6, Maryam Mofidi Nejad2, Shahab Alizadeh7.
Abstract
Background and Aims: Epidemiologic studies show a strong association between chronic inflammation and type 2 diabetes (T2D). Diet may also affect the risk of T2D by modulating inflammation. This meta-analysis aimed to assess the relation of dietary inflammatory index (DII) and risk of T2D.Entities:
Mesh:
Year: 2022 PMID: 35685508 PMCID: PMC9159166 DOI: 10.1155/2022/9953115
Source DB: PubMed Journal: Int J Clin Pract ISSN: 1368-5031 Impact factor: 3.149
Figure 1Flow chart of study.
Characteristics of studies.
| Population | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Reference | Year | Study design | Location | No. of participants | Sex | Age (range or mean ± SD) | Exposure assessment | Outcome assessment | Diabetes was the primary outcome, and analyses were adjusted for potential confounders |
| Woudenbergh et al. | 2013 | Cross-sectional | Netherlands | 1024 | M/F | 64 ± 9 | FFQ | FPG-2-h, -HbA1c | No |
| Shivappa et al. | 2014 | Cross-sectional | USA | 34703 | F | 61.58 ± 4.2 | FFQ | Self-report | No |
| Alkerwi et al. | 2015 | Cross-sectional | Luxembourg | 1352 | M/F | 44.25 ± 0.8 | FFQ | Medication use | No |
| Garcia-Arellano et al. | 2015 | Cross-sectional | Spain | 7216 | M/F | 67 ± 6 | FFQ | Medical record | No |
| Ramallal et al. | 2015 | Cross-sectional | Spain | 18794 | M/F | 38 ± 12 | FFQ | Medical record | No |
| Sánchez-Villegas et al. | 2015 | Cross-sectional | Spain | 15093 | M/F | 38.28 | FFQ | Medical record | No |
| Ruiz-Canela et al. | 2015 | Cross-sectional | Spain | 4145 | F | 68 ± 6 | FFQ | Medical record | No |
| Ruiz-Canela et al. | 2015 | Cross-sectional | Spain | 3091 | M | 66 ± 7 | FFQ | Medical record | No |
| Shivappa et al. | 2015 | Case-control | Italy | 978 | M/F | 62.5 | FFQ | Medical record | No |
| Xu et al. | 2015 | Cross-sectional | Sweden | 1942 | M/F | 70.6 ± 0.6 | 7-day dietary record | FPG ≥ 126 mg/dL, 2 h glucose ≥ 200 mg/dL, hypoglycemic agents or insulin use | No |
| Antwi et al. | 2016 | Case-control | USA | 2573 | M/F | 66.7 ± 10.3 | FFQ | Medical records | Yes |
| Moslehi et al. | 2016 | Cross-sectional | Iran | 2975 | M/F | 45 ± 11.7 | FFQ | FPG ≥ 126 mg/dL, 2 h glucose ≥ 200 mg/dL, use of antidiabetic medication | Yes |
| Vissers et al. | 2016 | Cross-sectional | Australia | 6972 | F | 52 ± 1 | FFQ | Doctor-diagnosed | No |
| Bergmans et al. | 2017 | Cross-sectional | USA | 11592 | M/F | 20-80 | 24-hour diet recall | Self-reported history | No |
| Bodén et al. | 2017 | Case-control | Sweden | 5284 | M | 53.85 ± 7.36 | FFQ | Self-report+FPG ≥ 7.0 mmol/L or 2 h glucose ≥ 11.1 mmol/L | No |
| Bodén et al. | 2017 | Case-control | Sweden | 1660 | F | 54.47 ± 8.28 | FFQ | Self-report+FPG ≥ 7.0 mmol/L or 2 h glucose ≥ 11.1 mmol/L | No |
| Phillips et al. | 2017 | Cross-sectional | Ireland | 2047 | M/F | 59.7 ± 0.17 | FFQ | FPG ≥ 7 mmol/L or doctor-diagnosed diabetes | No |
| Shivappa et al. 1 | 2017 | Cross-sectional | Germany | 1297 | M | 54.5 ± 5.8 | 7-day dietary record | Self-report | No |
| Shivappa et al. 2 | 2017 | Cross-sectional | USA | 12366 | M/F | 47.4 ± 19.1 | 24-hour diet recall | Self-report | No |
| Vissers et al. | 2017 | Cross-sectional | Australia | 7169 | F | 52 ± 1 | FFQ | Doctor-diagnosed | No |
| Denova-Gutiérrez et al. | 2018 | Cross-sectional | Mexico | 1174 | M/F | 39.9 ± 0.48 | FFQ | FPG ≥ 126 mg/dL and HbA1c> 6.5% | Yes |
| Farhangi et al. | 2018 | Cross-sectional | Iran | 454 | M/F | 59.02 ± 9.07 | FFQ | - | No |
| Hodge et al. | 2018 | Cross-sectional | Australia | 39532 | M/F | 55.3 ± 8.5 | FFQ | Structured interview | No |
| Mazidi et al. | 2018 | Cross-sectional | USA | 21 649 | M/F | 47.3 ± 0.25 | 24-hour diet recall | Questionnaire | No |
| McMahon et al. | 2018 | Cross-sectional | USA | 40161 | M | 45-69 | FFQ | Questionnaire and medical record | No |
| Rouhani et al. | 2018 | Cross-sectional | Iran | 221 | M/F | 56.57 ± 15.32 | FFQ | Self-report | No |
| Tomata et al. | 2018 | Cross-sectional | Japan | 793 | M/F | 75.2 ± 4.5 | Dietary history questionnaire | Self-report | No |
| Shivappa et al. | 2018 | Cross-sectional | Italy | 20823 | M/F | 55.32 ± 11.6 | FFQ | FPG ≥ 126 mg/dL, medication use | No |
| Wirth | 2018 | Cross-sectional | USA | 26046 | M/F | 46.1 ± 0.29 | 24-hour diet recall | Self-report | No |
| Zheng et al. | 2018 | Cross-sectional | USA | 101449 | M/F | 65.52 ± 0.04 | FFQ | Medical history | No |
| Abdulahi et al. | 2019 | Cross-sectional | Iran | 300 | M/F | 42.9 ± 10.9 | FFQ | FPG ≥ 126 mg/dL | Yes |
| Guinter et al. | 2019 | Cohort | USA | 6016 | M | 48.2 ± 10.02 | 3-day diet record | Self-report of medication use, self-reports by their personal physician | Yes |
| King et al. | 2019 | Cross-sectional | USA | 4434 | M/F | 49.4 | 24-hour diet recall | HbA1c (%)> 6.5, self-report | Yes |
| Laouali et al. | 2019 | Cohort | France | 70991 | F | 53 ± 6.7 | Dietary history questionnaire | FPG ≥ 7.0 mmol/L or random glucose ≥11.1 mmol/L at diagnosis, use of a glucose-lowering medication, or HbA1c level ≥53 mmol/mol (7.0%) | Yes |
| Agraib et al. | 2019 | Case-control | Jordan | 388 | M/F | 51.85 ± 10.2 | FFQ | Interview-based standardized questionnaire | No |
| Asadi et al. | 2019 | Cross-sectional | Iran | 4672 | M/F | 49.25 ± 7.85 | FFQ | - | No |
| Bondonno et al. | 2019 | Cross-sectional | Australia | 1422 | F | 75.2 ± 2.7 | FFQ | Medical history | No |
| Morimoto et al. | 2019 | Cross-sectional | Brazil | 684 | M | 59.7 ± 13.5 | 24-hour diet recall | Medical history | No |
| Morimoto et al. | 2019 | Cross-sectional | Brazil | 1585 | F | 59.7 ± 13.5 | 24-hour diet recall | Medical history | No |
| Mark Park et al. | 2019 | Cross-sectional | USA | 1815 | M/F | 41 | 24-hour diet recall | FPG ≥ 100 mg/dL or antidiabetic medication use, HOMA-IR ≥ 90th | No |
| Mark Park et al. | 2019 | Cross-sectional | USA | 1918 | M/F | 48.7 | 24-hour diet recall | FPG ≥ 100 mg/dL or antidiabetic medication use, HOMA-IR ≥ 90th | No |
| Tyrovolas et al. | 2019 | Cross-sectional | Greece | 3042 | M/F | 45 ± 14 | FFQ | Self-report | No |
| Veronese et al. | 2019 | Cross-sectional | Italy | 1565 | M/F | 65.5 ± 8.9 | FFQ | Self-report | No |
| Zheng et al. | 2019 | Cross-sectional | USA | 533256 | M/F | 61.68 ± 0.02 | FFQ | Self-report | No |
| Hoon Lee et al. | 2020 | Cross-sectional | USA | 19666 | M/F | 52.7 ± 9.6 | FFQ | Self-report | Yes |
| Asadi et al. | 2020 | Cross-sectional | Iran | 4365 | M/F | 49.14 ± 7.88 | FFQ | - | No |
| Herrou et al. | 2020 | Cross-sectional | France | 15096 | M/F | 60.5 ± 5.88 | 24-hour diet recall | Medical record | No |
| Lee et al. | 2020 | Cross-sectional | Korea | 1712 | M | 52.14 ± 0.2 | 24-hour diet recall | - | No |
| Lee et al. | 2020 | Cross-sectional | Korea | 2473 | F | 52.87 ± 0.2 | 24-hour diet recall | - | No |
| Li et al. | 2020 | Cross-sectional | USA | 210145 | M/F | 46.9 ± 9.2 | FFQ | Self-report | No |
| Li et al. | 2020 | Cross-sectional | USA | 210145 | M/F | 46.9 ± 9.2 | FFQ | Self-report | No |
| Li et al. | 2020 | Cross-sectional | USA | 210145 | M/F | 46.9 ± 9.2 | FFQ | Self-report | No |
| Wang et al. | 2020 | Cross-sectional | USA | 6893 | M/F | 69.66 ± 0.3 | 24-hour diet recall | FPG ≥ 126 mg/dL, 2 h glucose ≥200 mg/dL, self-report, insulin use | No |
| Wang et al. | 2020 | Cross-sectional | China | 1064 | F | 65 ± 0.5 | FFQ | Medical history | No |
| Zabetian-Targhi et al. | 2020 | Cross-sectional | Australia | 706 | M/F | 67.7 ± 6.9 | FFQ | RPG ≥ 199.8 mg/dL, FPG ≥ 126 mg/dL, 2 h glucose ≥199.8 mg/dL | No |
M: male; F: female; FFQ: food frequency questionnaire; FPG: fasting plasma glucose; RPG: random plasma glucose; HbA1c: hemoglobin A1c; HOMA-IR: homeostatic model assessment for insulin resistance
Subgroup analysis for the association between dietary inflammatory index and type 2 diabetes.
| Subgroup by | Effect sizes |
|
| OR (95% CI) |
|---|---|---|---|---|
| All studies | 55 | 96.5 | ≤0.001 | 1.03 (0.91–1.15) |
| Study quality | ||||
| High quality | 8 | 96.8 | ≤0.001 | 1.58 (1.15–2.17) |
| Low quality | 47 | 96.4 | ≤0.001 | 0.95 (0.84–1.08) |
| Sex | ||||
| Male | 7 | 51.3 | 0.05 | 1.01 (0.85–1.19) |
| Female | 10 | 72.1 | ≤0.001 | 0.88 (0.75–1.03) |
| Both | 38 | 97.3 | ≤0.001 | 1.07 (0.92–1.24) |
| Dietary assessment | ||||
| 24-hour recall | 13 | 94.4 | ≤0.001 | 1.05 (0.84–1.31) |
| 7-day dietary record | 3 | 87.5 | ≤0.001 | 0.74 (0.36–1.52) |
| Food frequency questionnaire | 37 | 97.0 | ≤0.001 | 1.04 (0.89–1.21) |
| Dilatory history questionnaire | 2 | 0.0 | 0.064 | 1.00 (0.89–1.11) |
There was more than 1 effect size for some studies.
Figure 2Meta-analysis for the association of dietary inflammatory index and risk of type 2 diabetes stratified by the quality of studies.
Figure 3Metaregression analysis for the effect of age on the relation of dietary inflammatory index to risk of type 2 diabetes.
Figure 4Funnel plot for publication bias.
Figure 5Sensitivity analysis by omitting one study at a time and reanalyzing other studies.